A New Highly Concentrated Insulin Aspart AT278 (500 U/ mL ) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71150 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Eva Svehlikova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Aspart, Hypoglycemic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To evaluate the pharmacokinetics, pharmacodynamics, and safety of a novel U500 insulin aspart formulation (AT278 [500 U/mL]; AT278‐U500) compared with standard concentration insulin aspart (InsAsp [100 U/mL]; InsAsp‐U100) and U500 human regular insulin (HumIns [500 IU/mL]; HumIns‐U500). Materials and Methods This single‐centre, randomised, double‐blind crossover 12‐h euglycaemic clamp study was conducted in 41 overweight and obese people with type 2 diabetes (BMI 25.0–38.7 kg/m 2 ) receiving a single subcutaneous dose (0.5 U/kg) of AT278‐U500 and InsAsp‐U100. HumIns‐U500 was consecutively studied open label in a 24‐h clamp.
Results
AT278‐U500 exhibited a significantly faster insulin absorption than InsAsp‐U100 and HumIns‐U500 ( t Early50%Cmax : 9 min vs. 35 min vs. 55 min), leading to a significantly higher glucose‐lowering effect within the first hour (AUC GIR,0‐60min ) compared with both InsAsp‐U100 (treatment ratio 2.02 [95% CI 1.64; 2.50]) and HumIns‐U500 (3.91 [2.89; 5.27]). When divided by median BMI (29.7 kg/m 2 ), AUC GIR,0‐60min was significantly higher with AT278‐U500 in both the low‐BMI and high‐BMI subgroup compared to InsAsp‐U100. Linear regression showed a significant inverse relationship between BMI and AUC GIR,0‐60min for InsAsp‐U100 (slope −0.142, p < 0.0001), whereas AT278‐U500 showed no such relationship. Overall insulin exposure was similar for AT278‐U500 and InsAsp‐U100, while overall glucose‐lowering effect was comparable across all three treatments.
Conclusions
AT278‐U500 maintains its ultra‐rapid onset characteristics independent of BMI, representing the first ultra‐rapid U500 option for prandial dosing in insulin‐resistant people with type 2 diabetes requiring high‐dose therapy. Trial Registration: ClinicalTrials.gov identifier: NCT05754424
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
- HEALTH - Institute for Biomedical Research and Technologies, Joanneum Research Forschungsgesellschaft mbH, Graz, Austria.
- Arecor Limited, Little Chesterford, UK.
ORCID-Profile: Eva Svehlikova, Christina Gatschelhofer, Bettina Lackner, Maria Ratzer, Gabriele Fluhr, Anja Stoisser, Thomas R Pieber
Zitieren
APA
Svehlikova, E., Gatschelhofer, C., Lackner, B., Ratzer, M., Fluhr, G., Stoisser, A., Kolaric, G., Gerring, D., Howell, S., Jezek, J., Lawrence, F., & Pieber, T. R. (2026). A New Highly Concentrated Insulin Aspart AT278 (500 U/ mL ) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71150
Vancouver
Svehlikova E, Gatschelhofer C, Lackner B, Ratzer M, Fluhr G, Stoisser A, et al. A New Highly Concentrated Insulin Aspart AT278 (500 U/ mL ) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71150
BibTeX
@article{Svehlikova2026,
author = {Svehlikova, Eva and Gatschelhofer, Christina and Lackner, Bettina and Ratzer, Maria and Fluhr, Gabriele and Stoisser, Anja and Kolaric, Gregor and Gerring, David and Howell, Sarah and Jezek, Jan and Lawrence, Fiona and Pieber, Thomas R},
title = {A New Highly Concentrated Insulin Aspart AT278 (500 U/ mL ) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71150}
}
EUVIMED